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Abstract 
HLTF is a transcription factor - The Helicase-Like 
Transcription Factor (HLTF/SMARCA3) belongs to 
the family of SWI/SNF proteins that use the energy 
of ATP hydrolysis to remodel chromatin in a variety 
of cellular processes.  
Several groups independently isolated HLTF 
through its capacity to selectively interact with a 
DNA cis-element in the promoter or enhancer of 
different genes involved in cardiac development 
during embryogenesis, cell cycle, collagen 
biogenesis, cell motility and angiogenesis.  
HLTF is a key element in DNA Damage Tolerance 
pathways - HLTF plays a role in DNA Damage 
Tolerance, especially in (i) translesion synthesis and 
(ii) template switching pathways (fork regression 
and strand invasion).  
HLTF is an E3 ubiquitin ligase targeting PCNA 
(K164) that results in DTT activation.  
The E3 ubiquitin ligase, translocase and HIRAN 
catalytic domain are the HLTF core activities. A key 
role in DNA repair was confirmed in vivo, in 2 
different Hltf null mouse models and showed that 
Hltf loss compromises error-free DNA replication 
and modulates mutagenesis by regulating proteins 
involved in the G2/M phase transition of the cell 
cycle in mouse heart and brain.  
HLTF is a tumor suppressor gene - In cancer, two 
mechanisms of HLTF inactivation are reported: (i) 
hypermethylation of its promoter and (ii) expression 
of truncated protein forms that have lost  
domains involved in DNA repair.  
These data support a role of tumor suppressor gene 
for HLTF.  
The first association between HLTF inactivation and 
tumorigenesis was shown when hypermethylation of 
the HLTF promoter was detected in 43% of primary 
colon tumors and 22-55% of gastric cancers.  
Moreover, HLTF deficiency in Apc-/+ mice induced 
the transition from colon adenocarcinoma to a 
carcinoma with high chromosomal instability. In 
head and neck, thyroid and uterus (cervix) cancers, 
an increased expression of two HLTF protein forms 
truncated in the carboxyl-terminal domain following 
alternative mRNA splicing was reported.  
These truncated HLTF forms have lost their DNA 
repair ability and might also have gained functions 
favouring cancer. 
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Identity 
HGNC (Hugo): HLTF 
Location: 3q24 
Other names: HIP116, HIP116A, HLTF1, RNF80, 
SMARCA3, SNF2L3, ZBU1, RUSH 
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Figure 1. Graphic representation of HLTF protein with its domains. Exon/intron structure of the human HLTF gene (upper 
line, after GenBank no.AJ418064) and domain organisation of the largest encoded protein (lower line after Genbank Z46606) 
(Debauve et al., 2008). The thin tilted lines link the 3' end of each exon to the last amino acid it encodes, except for exons 1 and 
25 where they indicate the 1st and last protein residues, respectively. The different protein domains are boxed: DBD (DNA 
binding domain), HIRAN (Hip116-Rad5 N-terminal domain; Lyer et al., 2006), SNF2_N (SNF2 family N-terminal domain), I to VI 
(7 helicase domains), RING (zinc finger domain associated with E3 ubiquitin ligase activity). 
DNA/RNA 
Description 
The HLTF gene is located at 3q 25.1-26.1 (Lin et al., 
1995); it is 56.4kb long and contains 26 exons. 
Transcription 
The alternative splicing of intron 25, mapped in the 
3'UTR, produces two mRNA of 5.4 and 4.5kb with 
identical coding capacity. Additional alternative 
splicing of exon 20 or intron 21 was observed in 
HeLa cells (Capouillez et al., 2009). 
In the rabbit, the RUSH 1alpha and beta protein 
variants result from progesterone- or estrogen-
dependent alternative splicing of the mRNA, 
respectively (Hayward-Lester et al., 1996). 
In the mouse, a transcriptome analysis of the heart 
and brain revealed the expression of a full-lenght 
HLTF RNA isoform (exons 1-25) and a spliced 
isoform (exons 1-21 + intron 21) in a ratio 26 :1 
(heart) and 5 :1 (brain) (Helmer et al., 2013 and 
2013a). 
Pseudogene 
None. 
Protein 
Note 
Translation of alternatively spliced mRNAs: 
The alternative use of start codons Met1 and  
Met123 in the same reading frame generates HLTF 
proteins of 115kDa and 110kDa, respectively (Ding 
et al., 1996). 
The rabbit orthologue of human HLTFMet123 is the 
RUSH-1alpha 113kDa protein; RUSH-1beta is a 
95kDa truncated version that results from alternative 
splicing of a 57bp exon (Chilton et al., 2008).  
In Hela cells two protein variants resulting from 
alternative splicing of exon 20 or intron 21 were 
observed: HLTF1ΔA (83kDa) and HLTF1ΔB 
(95kDa). These proteins have lost domains needed 
for DNA repair activity (Capouillez et al., 2009). 
Description 
HLTF belong to the SWI/SNF family of chromatin 
remodelling enzymes.  
The protein contains: (a) a HIP116 Rad5p N-
terminal (HIRAN) domain embedded in a larger 
DNA-binding domain, (b) a Sucrose Non-
Fermenting 2 (SNF2) amino-terminal dimerization 
domain, (c) seven conserved DNA helicase/ATPase 
domains, characteristic of SWI/SNF2 family 
members and (d) a Really Interesting New Gene 
(RING) finger domain (Dhont et al., 2015) (see 
diagram 1). The HLTF1ΔA protein form has lost the 
RING domain and the last 3 helicase domains. 
HLTF1ΔB form has only lost the last 3 helicase 
domains (Capouillez et al., 2009).  
Both proteins are predicted to have lost DNA repair 
activity. 
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Expression 
Development: 
During mouse embryogenesis, Zbu1 (mouse HLTF) 
transcripts are detected relatively late in foetal 
development and increase in neonatal stages, 
whereas the protein accumulates asynchronously in 
heart, skeletal muscle, and brain. In adult human 
tissues, alternatively spliced Zbu1 transcripts are 
ubiquitous with highest expression in the same 
tissues (Gong et al., 1997). Sandhu and colleagues 
built a Hltf -/- mouse by replacing Hltf with LacZ, in 
order to track Hltf expression during embryogenesis. 
They found that Hltf was specifically expressed in 
the heart at an early developmental stage (E8.5 to 
E9.5). Hltf exhibited a broader expression pattern at 
E10.5, with LacZ signals detected in somites, 
branchial arches, limb bud and brain. At later 
embryonic developmental stages, such as E16.5, Hltf 
showed wide and strong expression in many tissues, 
including heart, lung, liver, kidney, spleen and 
pancreas. This wide-spread expression of Hltf was 
also observed in adult mice. In both adult intestine 
and colon, Hltf expression was mainly detected in 
the crypts and in the intestinal epithelial cells 
(Sandhu et al., 2012). 
Expression profile: 
Find link to expression profile: HLTF (T1D 
database) 
Transcription regulation: 
In the uterus rabbit HLTF expression is repressed by 
estrogens and induced by progesterone (Hayward-
Lester et al., 1996). 
The rabbit HLTF (RUSH) promotor has no TATAA 
box and the transcription start site maps on an 
initiator/downstream element (Inr-DPE). Two 
Sp1/Sp3 binding sites in the proximal promoter 
repress basal transcription. These features are 
conserved in the human gene promoter. In addition 
the rabbit HLTF promoter is repressed by NF-Y and 
HLTF itself and activated by progesterone 
(Hewetson and Chilton, 2003). In response to 
progesterone the HLTF (RUSH 1alpha) protein 
binds to a distal site in the promoter of its own gene 
and is involved in DNA looping by interaction with 
Egr-1/c-Rel bound to one of the Sp1/Sp3 sites 
mentioned above. This interaction represses 
progesterone induction (Chilton and Hewetson, 
2008). 
Protein regulation: 
Kim and colleagues showed that HLTF undergoes a 
negative regulation by CHFR, a E3 ubiquitin ligase. 
Both proteins interact in vitro and in vivo and as 
CHFR levels increase, HLTF levels decrease 
accordingly. Proteasome inhibitor (MG132) reverts 
this effect on HLTF stability, suggesting its 
degradation is mediated by ubiquitin-proteasome 
system. They also proved that HLTF half-life was 
shortened in presence of CHFR (Kim et al., 2010). 
Qing and colleagues showed that HLTF was 
positively regulated by USP7, a deubiquitination 
enzyme, which interacts with HLTF in vitro and in 
vivo and stabilizes it without any competition with 
CHFR (Qing et al., 2011). 
Cancer: 
Two lines of evidence have lead to the conclusion 
that HLTF was a tumor suppressor gene. A first set 
of publications showed aberrant hypermethylation of 
the HLTF promoter leading to its silencing in various 
cancer types. Then two publications demonstrated 
that the HLTF protein was involved in post 
replication DNA repair and that its inactivation leads 
to chromosome rearrangements. 
The HLTF promotor is hypermethylated in 43% of 
primary colon cancer (Moinova et al., 2002) and is 
frequently methylated in adenomas and 
hepatocarcinomas. Kim et al. (2006) found that the 
HLTF inactivation by promoter hypermethylation 
was associated with the first stages of 
carcinogenesis.  For a detailed analysis, see Dhont et 
al., 2015. 
Localisation 
Intracellular localisation. 
In head and neck, and thyroid cancer progression a 
significant shift of HLTF expression from the 
cytoplasm toward the nuclear compartment was 
observed (Capouillez et al., 2008). 
Function 
DNA-binding protein:  
HLTF was isolated independently (and given 
different names) by different groups based on its 
interaction with different genes (see table below). 
Name Target gene Reference 
HIP116 
(human) 
HIV promoter; SV40 
enhancers 
Sheridan et al., 1995 
HLTF 
(human) 
PAI-1 (SERPINE1) 
promoter 
Ding et al., 1996 
P113 
(mouse) 
PAI-1 (SERPINE1) 
promoter 
Zhang et al., 1996 
RUSH 
(rabbit) 
Uteroglobin promoter 
Hayward-Lester et 
al., 1996 
Zbu1 
(mouse) 
Myosin light chain 
enhancer 
Gong et al., 1997 
HLTF 
(human) 
B-globin locus 
control region 
Mahajan and 
Weissman, 2002 
Transcriptional activity:  
The HLTFMet123 variant activates the SERPINE1 
(PAI-1) promoter in synergy with Sp1 or Sp3. This 
synergy involves protein/protein and protein/DNA 
interactions (Ding et al., 1996; Ding et al., 1999). 
Two different consensus sequences recognized by 
HLTF were discovered: (A/G)G(T/C)(G/T)G (Ding  
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et al., 1996) and (C/A)C(T/A)TN(T/G) (Hayward-
Lester et al., 1996). The latter one was used by 
Genomatix (MatInspector; Cartharius et al., 2005) to 
develop an algoritm to find putative HLTF binding 
sites.  
HLTF can activate gene transcription either alone or 
with different protein partners according to the cell 
type and the target gene (i.e., SP1/ SP3 for 
SERPINE1 (Ding et al., 1996 and 1999), NONO and 
SFPQ for PRL (Guillaumond et al., 2011), LEF1 and 
MITF for OCA2 (Visser et al., 2012)). It binds a 
promoter (i.e. SERPINE1 or PRL) or an enhancer 
(i.e., intron 86 of HERC2 for OCA2 expression) and 
involves a long distance chromatin looping (Visser 
et al., 2012) for PRL expression (Guillaumond et al., 
2011) and its own downregulation mediated by Erg-
1 and REL (Hewetson et al., 2008). See also Dhont 
et al., 2015. 
Chromatin remodelling:  
Similarly to other SNF/SWI proteins, HLTF could 
play a role in chromatin remodelling. It has the 7 
helicase domains and presents a DNA-dependent 
ATPase activity (Sheridan et al., 1995; Hayward-
Lester et al., 1996; MacKay et al., 2009). 
E3 ubiquitin ligase activity:  
The RING domain insures protein-protein 
interactions in E3 ubiquitin ligases. It allows specific 
targeting of the substrate proteins for transfer of 
ubiquitin by the associated E2 ubiquitin ligase. The 
HLTF RING domain is situated between helicase 
domains III and IV and is strongly conserved in 
evolution. HLTF and its homologue SHPRH are the 
functional orthologues of Rad5 in S. cerevisiae, 
which mediates the polyubiquitination of PCNA 
lysine 63 when damage is detected on the lagging 
DNA strand during replication (Unk et al., 2008; 
Motegi et al., 2008). The HLTF E3 ubiquitin ligase 
activity was confirmed with a range of E2 ubiquitin 
ligases (MacKay et al., 2009). 
DNA repair: 
The SNF2 domain is situated between the HLTF 
DBD and the first helicase domain. It is present in a 
large variety of proteins implicated in DNA repair, 
recombination, chromatin remodelling and 
transcription (Eisen et al., 1995; Linder et al., 2004). 
In addition, part of the HLTF DNA binding domain 
is conserved in SWI2/SNF2 proteins such as 
RAD5P: this domain was named HIRAN based on 
one of the HLTF alternatives names (HIP116) and 
the Rad5p N-terminal domain. HLTF is involved in 
post replication DNA repair (Unk et al., 2008; 
Motegi et al., 2008). HLTF can complement the 
ultraviolet (UV) sensitivity of rad5- yeast cells, thus 
strongly supporting a role in postreplication DNA 
repair (Unk et al., 2008). Hltf-deficient mouse 
embryonic fibroblasts show elevated chromosome 
breaks and fusions after methyl methane sulfonate 
treatment (Motegi et al., 2008). In addition the HLTF 
protein interacts with PAXIP1 (PTIP) and RPA70, 
both involved in DNA replication and repair 
(MacKay et al., 2009).  
When DNA damaged, the replication fork stalls and 
leads to cell death. DNA damage tolerance pathways 
are activated through PCNA ubiquitination. RAD6- 
RAD18 and HLTF control this pathways. HLTF is 
preferentially recruited when DNA is damaged by 
UV and inhibits its counterpart SHPRH in that case. 
However, if DNA is damaged by methyl-methan 
sulfonate (MMS), HLTF degradation is triggered 
and SHPRH is activated (Lin et al., 2011). HLTF 
activates translesion synthesis by monoubiquinating 
PCNA and by recruiting the error-free DNA 
polymerase POLH ID: 303> (Polη). HLTF also 
activates template switching by polyubiquitinating 
PCNA. Its HIRAN domain is essential in the 
recognition of stalled DNA replication fork (a 3'-
hydroxyl group (3'-OH) on the nascent leading 
strand, which mimics a site of two unpaired 
nucleotides) and its restart (Kile et al., 2015), in 
concert with it helicase domains (Blastyàk et al., 
2010). Beside this role, HLTF exhibits an ATP 
hydrolysis-dependent protein remodeling activity at 
stalled replication fork: HLTF catalyzes the 
clearance of roadblocks in replication fork restart 
(Achar et al., 2011).  
HLTF can also promote the intrusion of the newly 
synthesized strand, stalled by a damage, in the sister 
chromatid to bypass the lesion (Burkovics et al., 
2013). Both RING and helicase domains are critical 
for this process (Blastyak et al., 2010). Studies on 
HLTF HIRAN domain revealed how HLTF 
recognizes a stalled replication fork and restarts it by 
fork regression (Hishiki et al., 2015; Ikegaya et al., 
2015). Stalled replication forks contain a 3'-hydroxyl 
group (3'-OH) on the nascent leading strand, which 
mimics a site of two unpaired nucleotides ("lesion"). 
HLTF specifically recognizes this "lesion" by its 
HIRAN domain pocket in which (i) the two unpaired 
nucleotides are stuck between two tyrosines (Y72 
and Y93) and (ii) the 3'-OH single DNA (ssDNA) 
end binds to an aspartate (D94) (Kile et al., 2015; 
Tsutakawa et al., 2015). Fork reactivation is also 
promoted via concerted mediation of TP53, POLI 
(POLι), HLTF and ZRANB3 (Hampp et al., 2016).  
Isoforms of RUSH (rabbit HLTF) interact with a 
RING-finger binding protein (RFBP), which is a 
splice variant of the Type IV P-type ATPase, 
ATP11B. This protein is a putative phospholipid 
pump, located in the inner nuclear membrane and the 
interaction with the HLTF RING domain is 
conserved in humans (Mansharamani et al., 2001; 
Hewetson et al., 2008). 
Homology 
SMARCA3 (chimpanzee: 99%; dog: 93%; cow: 
91% identity) 
RUSH-1-alpha and RUSH-1-beta (rabbit: 91% and 
90% identity) 
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P113 (rat and mouse: 83% identity) 
MGC131155 (Xenopus leavis: 63% identity) 
RAD5B (Saccharomyces cerevisiae: 25, 7% 
identity) 
Implicated in 
Colorectal cancer 
HLTF promoter methylation is rare in normal colon 
tissue (3.0-10.2 %). However, it is increased in colon 
adenoma (25.7-68.5 %) and remains stable or 
slightly increased in invasive carcinomas (34.3-41.4 
%), independently of tumor stage (reviewed in 
Dhont et al., 2015). Colorectal cancers with a highly 
methylated panel of genes, including HLTF, are 
associated with the absence of lymph nodes 
metastasis and with a poorly differentiated histology 
(Hibi et al., 2005 and 2006). HLTF promoter 
hypermethylation alone was significantly less 
frequent in non-metastatic (Dukes's stages B and C) 
than in metastatic (Duke's stage D) primary cancers 
(reviewed in Dhont et al., 2015). 
Prognosis 
HLTF promoter hypermethylation alone or with a 
panel of other genes is an independent pejorative 
prognostic factor in colorectal cancer, associated 
with a shorter survival and higher risk of disease 
recurrence. It also correlated with larger tumor size, 
higher stage and grade, and metastatic disease 
(reviewed in Dhont et al., 2015). 
Gastric carcinoma 
The HLTF promoter hypermethylation has been 
detected in approximately 20-55% of primary gastric 
cancers (Hibi et al., 2003; Hamai et al., 2003; Kim et 
al., 2006; Leung et al., 2003; Oue et al., 2006). For 
patients with family histories HLTF gene silencing 
is probably an early stage of gastric carcinogenesis. 
HLTF mRNA expression has been studied in 
different gastric carcinoma cell lines and Hamai et 
al., 2003 have shown that the KATO-III cells present 
loss of HLTF expression associated with its 
promoter methylation. A chromatin 
immunoprecipitation assay revealed that the 
acetylation levels of histones H3 and H4 in the 5' 
CpG island of the HLTF gene were inversely 
associated with DNA methylation status. These 
findings support a model in which methyl-CpG-
binding proteins act as anchors on methylated DNA, 
recruiting accessory proteins, such as HDAC, that 
contribute to build a repressive chromatin structure. 
Esophageal squamous cell 
carcinoma (ESCC) 
The HLTF promoter was found methylated in 1  
case out of 40, suggesting that it is not a common 
target for epigenetic gene silencing in ESCC (Hibi et 
al., 2003). 
Prognosis 
This cancer is very aggressive and with a poor 
prognosis. 
Uterine cancer 
HLTF promoter hypermethylation was found in 22% 
of uterine cancers, but it was more frequently 
methylated in cervical adenocarcinomas (43%) and 
in endometrial adenocarcinomas.  
These findings suggest that HLTF promoter 
hypermethylation may predispose to the 
development of specific types of human uterine 
cancer (Kang et al., 2006).  
HLTF immunodetection increased during the 
oncogenesis in cervical cancer (Capuillez et al., 
2011): cervix carcinomas (SCC, AD and AD in situ) 
exhibited the highest HLTF immunostaining. 
Truncated protein forms were detected in SCC (no 
data about AD and AD in situ). No correlation with 
clinical data was presented in this study. In addition, 
Cho et al. (2011) showed HLTF overexpression in 
recurrent cervical carcinoma following radiation 
treatment compared with patients with former 
cervical cancer without recurrence; this might confer 
radiation resistance in cervical cancer, but the HLTF 
protein form expressed in these cases was not 
determined. Ye et al. (2015) also showed that HLTF 
mRNA was a target of MIR145, which is decreased 
in cervical cancers and is associated with radio-
sensitivity. Indeed, MIR145 and HLTF expression 
levels were inversely correlated in radio-resistant 
cervical cancers. 
Abnormal protein 
In cervix cancer, truncated forms of HLTF proteins 
were detected. These forms result from an alternative 
splicing of HLTF mRNA (Exons 19-22). 
Renal cancer 
Experimental model of estrogen-induced 
carcinogenesis in hamster. Early overexpression of 
HLTF in tumor buds (Debauve et al., 2006). 
Determination of human iris colour 
(blue/brown eye colour) 
See Sturm et al., 2008 and Sturm et al., 2009. 
Disease 
None 
Cytogenetics 
The identified SNP (rs 12913832 T/C) in the OCA2 
intron 86 of the HERC2 locus serve as a target for 
the SWI/SNF family member HLTF. 
Hybrid/Mutated gene 
None 
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Figure 2. Model for the determination of the blue-brown eye colour based upon regulation of OCA2 gene expression (Sturm 
et al., 2009). 
Abnormal protein 
None 
Head and Neck Cancers 
HLTF expression was assessed by 
immunohistochemistry followed by microscopy 
computer-assisted quantification and 
immunodetection on western blots.  
In HSCC, HLTF staining increased from tumor-free 
tissue to carcinoma, associated with a protein shift 
from the nucleus to the cytoplasm between dyplasias 
and carcinomas.  
In LSCC, HLTF expression decreased from tumor-
free tissue to carcinomas, associated with a nucleo-
cytoplasmic translocation in dyplasias and 
carcinomas (Capouillez et al., 2008 and 2009). 
Disease 
Hypopharyngeal (HSCC) and Laryngeal Squamous 
Cell Carcinoma (LSCC) 
Prognosis 
In HSCC, HLTF detection is an independent 
prognostic marker of disease recurrence.  
In LSCC, there is a trend of a higher risk of 
recurrence in low-HLTF carcinoma. 
Abnormal protein 
In both HSCC and LSCC, truncated forms of HLTF 
proteins were detected.  
These forms result from an alternative splicing of 
HLTF mRNA (Exons 19-22). 
Thyroid Cancer 
HLTF expression was assessed in two independent 
cohorts.  
In the first cohort (80 patients), HLTF expression 
was compared among adenoma, papillary 
carcinoma, follicular carcinoma and anaplastic 
carcinoma: adenomas presented strong nuclear 
HLTF immunostaining, whereas carcinomas 
exhibited HLTF only in the cytoplasm.  
In the second cohort (69 patients), benign thyroid  
lesions (including 10 colloid nodules, 16 follicular 
adenomas, 7 Hashimoto's thyroiditis, and 7 Grave's 
disease) and malignant lesions (including 17 
papillary carcinomas and 12 follicular variant of 
papillary carcinomas) were compared.  
HLTF staining was strong and primarily located in 
nuclei in benign lesions, and it was weaker and 
shifted to the cytoplasm in malignant lesions. 
Interestingly, thyroid immune diseases (Hashimoto 
and Graves's diseases) harbored lower HLTF 
expression within the benign lesion group (Arcolia 
et al., 2014). 
Disease 
Thyroid adenoma and carcinoma (papillary, 
follicular, and anaplastic), Hashimoto's thyroiditis 
and Grave's disease. 
Prognosis 
HLTF was proposed as a biomarker in the 
differential diagnosis of benign and malignant 
thyroid lesions. 
To be noted 
Note 
Alternative splicing variants: Ref: Capouillez et 
al., 2009 
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Figure 3. Alternative splicing and encoded proteins of HLTF.  For each HLTF protein form, the name, number of amino acids 
and the theoretical molecular weight (kDa) are indicated (left). Met1 is the first methionine, corresponding to the first translation 
start site, and Met123 is the methionine 123, corresponding to the alternative translation start site (exon 3). The protein domains 
are indicated as colored boxes. DBD (orange): DNA binding domain. SNF2 (blue): SNF2 domain. Yellow boxes from I to VI: 
Helicase/ATPase domains. RING (green): RING domain. The white flag "NLS" represents the nuclear localization signal (amino-
acids KRRK at position 380 encoded by exons 10-11). Above each protein, the mRNA area of exons 19-22 is represented. This 
area is subjected to alternative splicing, resulting in protein forms truncated at the carboxyl-terminus. Exons and introns are 
represented as colored rectangles. The red crosses indicate the early stop codons, resulting from reading frameshifts (Dhont et 
al., 2015) 
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